RxDoctor Payments DataLook up a doctor →

Jose Cardenas, MD

Neurology · Aiken, SCNPI 1245279314

Payments from drug & device makers

$215,768in general payments, 2019–2025

Across 1,290 payments — averaging $167.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$59K
  • AbbVie$43K
  • Amgen$40K
  • Teva Pharmaceuticals USA, Inc.$23K
  • Biohaven Pharmaceutical Holding Company Ltd.$21K
  • Biohaven Pharmaceuticals, Inc.$15K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$10,7755%
  • Speaking & faculty fees$176,66082%
  • Grants$880%
  • Travel & lodging$5,8063%
  • Food & beverage$22,41210%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC124$59,382
AbbVie(2 entities)248$42,752
Amgen(2 entities)79$39,729
Teva Pharmaceuticals USA, Inc.144$23,174
Biohaven Pharmaceutical Holding Company Ltd.31$20,917
Biohaven Pharmaceuticals, Inc.20$15,195
Lundbeck LLC39$2,454
Acadia Pharmaceuticals Inc44$1,082
SK Life Science, Inc.37$976
UCB, Inc.46$952
Neurocrine Biosciences, Inc.46$943
Pfizer37$655
EMD Serono, Inc.27$634
Eisai Inc.28$560
AstraZeneca(2 entities)24$510
Novartis30$500
MDD US Operations, LLC21$448
Biogen23$415
Supernus Pharmaceuticals, Inc.40$401
Argenx US, Inc.14$394
Sanofi18$374
Johnson & Johnson19$335
Livanova USA, Inc.8$333
Otsuka America Pharmaceutical, Inc.11$230
Sunovion Pharmaceuticals Inc.14$227
Boston Scientific5$178
Scilex Pharmaceuticals Inc.8$175
Zyla Life Sciences, Inc.14$154
Adamas Pharmaceuticals, Inc.9$138
Amneal Pharmaceuticals LLC7$126
Avanir Pharmaceuticals, Inc.11$123
Upsher-smith Laboratories LLC7$119
Arbor Pharmaceuticals, Inc.6$104
Impel Pharmaceuticals Inc.5$104
Grifols USA, LLC3$82
Assertio Therapeutics, Inc.5$81
Medtronic(2 entities)2$74
Takeda Pharmaceuticals U.S.A., Inc.3$74
Neurelis, Inc.3$74
Alnylam Pharmaceuticals Inc.3$56
Genentech USA, Inc.3$54
Axsome Therapeutics, Inc.2$43
Jazz Pharmaceuticals Inc.2$38
Portola Pharmaceuticals, LLC1$32
Vanda Pharmaceuticals Inc.1$31
Merz Pharmaceuticals, LLC1$31
Promius Pharma LLC2$30
Avion Pharmaceuticals2$28
Inspire Medical Systems, Inc.1$26
Octapharma USA, Inc.1$24
Otsuka Pharmaceutical Development & Commercialization, Inc.1$24
Catalyst Pharmaceuticals, Inc.1$22
Azurity Pharmaceuticals, Inc.1$21
Aprecia Pharmaceuticals, LLC1$21
Almatica Pharma LLC1$19
Banner Life Sciences, LLC1$17
Zimmer Biomet1$16
Currax Pharmaceuticals LLC1$16
Hospira, Inc.1$15
E.r. Squibb & Sons, L.L.C.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$215,768 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$120,218
Medicare patients
549
Services billed
1,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate30$176,891
Austedo XrDeutetrabenazine14$126,997
Aimovig AutoinjectorErenumab-Aooe89$78,533
Emgality PenGalcanezumab-Gnlm66$54,495
UbrelvyUbrogepant45$54,226
Nurtec OdtRimegepant Sulfate47$51,363
BotoxOnabotulinumtoxina23$30,177
XcopriCenobamate23$26,609
RexultiBrexpiprazole17$25,722
AptiomEslicarbazepine Acetate12$16,423
Emgality SyringeGalcanezumab-Gnlm12$10,564
ReyvowLasmiditan Succinate11$9,411
Memantine Hcl159$6,993
Levetiracetam170$6,758
Primidone102$4,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,082$176,89130 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$23,174$126,99714 claims
AbbVieUbrelvy, Botox$42,752$84,40368 claims
PfizerNurtec Odt$655$51,36347 claims
SK Life Science, Inc.Xcopri$976$26,60923 claims
Otsuka America Pharmaceutical, Inc.Rexulti$230$25,72217 claims
Sunovion Pharmaceuticals Inc.Aptiom$227$16,42312 claims
Lilly USA, LLCReyvow$59,382$9,41111 claims
Upsher-smith Laboratories LLCTopiramate$119$1,59172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.

Other neurology in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →